Literature DB >> 17579931

Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: the Ontario experience.

Leslie Levin1, Ron Goeree, Nancy Sikich, Birthe Jorgensen, Melissa C Brouwers, Tony Easty, Catherine Zahn.   

Abstract

OBJECTIVES: The aim of this study was to describe a comprehensive continuum that has developed in Ontario between government and key stakeholder groups, including hospitals, physicians, academic institutions, clinical epidemiologists, health economists, industry, and bioethicists to achieve evidence-based recommendations for policy development.
METHODS: The various components of the comprehensive model that has evolved to develop an evidentiary platform for policy development are summarized, and the flow between these components is described.
RESULTS: The development of the Ontario Health Technology Advisory Committee (OHTAC) and associated programs demonstrate the need to go beyond the traditional steps taken within most health technology assessment paradigms. These components include pragmatic postmarketing studies, human factors, and safety analyses, and formalized interactions with a broad spectrum of potential end-users of each technology, experts, and industry. Thesecomponents, taken together with an expanded systematic review to include a range of economic analyses, and societal impacts augment the traditional systematic review processes. This approach has been found to be important in assisting decision making and has resulted in an 81 percent conversion from evidence to policy consideration for eighty-three technologies that had been assessed at the time this article was submitted.
CONCLUSIONS: The comprehensive model, centered around OHTAC, has added important new dimensions to health policy by improving its relevance to decision makers and providing an accountable and transparent basis for government to invest appropriately in health technologies. This study could also form a basis for further research into appropriate methodologies and outcome measurements as they relate to each component of this approach.

Entities:  

Mesh:

Year:  2007        PMID: 17579931     DOI: 10.1017/s0266462307070456

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  10 in total

1.  EBM, HTA, and CER: clearing the confusion.

Authors:  Bryan R Luce; Michael Drummond; Bengt Jönsson; Peter J Neumann; J Sanford Schwartz; Uwe Siebert; Sean D Sullivan
Journal:  Milbank Q       Date:  2010-06       Impact factor: 4.911

2.  Access with evidence development in the UK: past experience, current initiatives and future potential.

Authors:  Andrew Briggs; Karen Ritchie; Elisabeth Fenwick; Kalipso Chalkidou; Peter Littlejohns
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Comparative effectiveness research in Ontario, Canada: producing relevant and timely information for health care decision makers.

Authors:  Danielle M Whicher; Kalipso Chalkidou; Irfan A Dhalla; Leslie Levin; Sean Tunis
Journal:  Milbank Q       Date:  2009-09       Impact factor: 4.911

Review 4.  Health technology funding decision-making processes around the world: the same, yet different.

Authors:  Tania Stafinski; Devidas Menon; Donald J Philippon; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

Review 5.  Research and advice giving: a functional view of evidence-informed policy advice in a Canadian Ministry of Health.

Authors:  Jonathan Lomas; Adalsteinn D Brown
Journal:  Milbank Q       Date:  2009-12       Impact factor: 4.911

6.  When do performance-based risk-sharing arrangements make sense?

Authors:  Michael Drummond
Journal:  Eur J Health Econ       Date:  2015-07

Review 7.  Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.

Authors:  Tania Stafinski; Christopher J McCabe; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  "We noticed that suddenly the country has become full of MRI". Policy makers' views on diffusion and use of health technologies in Iran.

Authors:  Mohammad Palesh; Carol Tishelman; Sten Fredrikson; Hamidreza Jamshidi; Göran Tomson; Azita Emami
Journal:  Health Res Policy Syst       Date:  2010-04-06

Review 9.  FROM TALK TO ACTION: POLICY STAKEHOLDERS, APPROPRIATENESS, AND SELECTIVE DISINVESTMENT.

Authors:  P Alison Paprica; Anthony J Culyer; Adam G Elshaug; Justin Peffer; Guillermo A Sandoval
Journal:  Int J Technol Assess Health Care       Date:  2015-08-20       Impact factor: 2.188

10.  Views of health system policymakers on the role of research in health policymaking in Israel.

Authors:  Moriah E Ellen; Einav Horowitz; Sharona Vaknin; John N Lavis
Journal:  Isr J Health Policy Res       Date:  2016-06-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.